S1P5

Bristol Myers Squibb Receives European Commission Approval of Zeposia (ozanimod) for use in Adults with Moderately to Severely Active Ulcerative Colitis

Retrieved on: 
Tuesday, November 23, 2021

The most common adverse reactions leading to discontinuation were related to liver enzyme elevations (1.1%) in the MS clinical studies.

Key Points: 
  • The most common adverse reactions leading to discontinuation were related to liver enzyme elevations (1.1%) in the MS clinical studies.
  • Bristol Myers Squibb thanks the patients and investigators involved in the True North clinical trial.
  • Bristol Myers Squibb is continuing to evaluate Zeposia in an open-label extension trial, which is ongoing and designed to assess the longer-term profile of Zeposia for the treatment of moderately to severely active UC.
  • The company is also investigating Zeposia for the treatment of moderately to severely active Crohns disease in the ongoing Phase 3 YELLOWSTONE clinical trial program.